Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis.

IF 2.9 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-24 DOI:10.1080/14737140.2024.2408278

Mingcan Zheng, Puxu Wang, Yuhang Wang, Zirui Jia, Jiacheng Gao, Xiaodong Tan, Hailong Chen, Guo Zu

{"title":"Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis.","authors":"Mingcan Zheng, Puxu Wang, Yuhang Wang, Zirui Jia, Jiacheng Gao, Xiaodong Tan, Hailong Chen, Guo Zu","doi":"10.1080/14737140.2024.2408278","DOIUrl":null,"url":null,"abstract":"Background: The research on the associations between tissue inhibitors of metalloproteinase-1 (TIMP1) expression and the clinicopathological characteristics and prognosis of patients with gastric cancer (GC) have resulted in contradictory findings. Exploring the associations between TIMP1 and clinicopathological parameters and the prognosis of GC patients is essential.Methods: We searched the literature in the databases according to the inclusion and exclusion criteria. Hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the relationships between TIMP1 expression and the clinicopathological parameters and prognosis of GC patients.Results: Nine studies with 1,200 GC patients were included. Our results indicated that TIMP1 expression was not related to sex, age, TNM stage, depth of invasion, lymph node metastasis, or tumor size in GC patients. However, TIMP1 expression was associated with the differentiation of GC. Furthermore, TIMP1 expression was associated with poor prognosis in GC patients.Conclusion: TIMP1 expression was related to tumor differentiation and poor prognosis but not sex, age, TNM stage, depth of invasion, lymph node metastasis or tumor size.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1169-1176"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2408278","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The research on the associations between tissue inhibitors of metalloproteinase-1 (TIMP1) expression and the clinicopathological characteristics and prognosis of patients with gastric cancer (GC) have resulted in contradictory findings. Exploring the associations between TIMP1 and clinicopathological parameters and the prognosis of GC patients is essential.

Methods: We searched the literature in the databases according to the inclusion and exclusion criteria. Hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the relationships between TIMP1 expression and the clinicopathological parameters and prognosis of GC patients.

Results: Nine studies with 1,200 GC patients were included. Our results indicated that TIMP1 expression was not related to sex, age, TNM stage, depth of invasion, lymph node metastasis, or tumor size in GC patients. However, TIMP1 expression was associated with the differentiation of GC. Furthermore, TIMP1 expression was associated with poor prognosis in GC patients.

Conclusion: TIMP1 expression was related to tumor differentiation and poor prognosis but not sex, age, TNM stage, depth of invasion, lymph node metastasis or tumor size.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胃癌中 TIMP1 表达的临床病理和预后意义：系统综述和荟萃分析。

背景：组织金属蛋白酶抑制剂-1（TIMP1）的表达与胃癌（GC）患者的临床病理特征和预后之间的关系研究结果相互矛盾。探讨 TIMP1 与胃癌患者临床病理参数和预后之间的关系至关重要：根据纳入和排除标准，我们在数据库中检索了相关文献。采用危险比（HRs）、几率比（ORs）和 95% 置信区间（95% CIs）来评估 TIMP1 表达与 GC 患者临床病理参数和预后之间的关系：结果：共纳入了 9 项研究，1,200 名 GC 患者。结果表明，TIMP1的表达与GC患者的性别、年龄、TNM分期、浸润深度、淋巴结转移或肿瘤大小无关。然而，TIMP1 的表达与 GC 的分化有关。此外，TIMP1的表达与GC患者的不良预后有关：结论：TIMP1的表达与肿瘤分化和预后不良有关，但与性别、年龄、TNM分期、浸润深度、淋巴结转移或肿瘤大小无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.